Observational Study Protocol: LIVER-R

← catalyst calendar

NCT06252753 · readout in 1,594 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With ICON plc.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

4,000estimated

Sites

159

Countries

Australia, Austria, Belgium +19

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-12-19

actual

When the study began enrolling

Primary completion

2030-12-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-12-30

estimated

The whole study's end, after follow-up

First posted

2024-02-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Hepatobiliary Cancers

Interventions

Other: Durvalumab-based combination therapies in observational study setting — also filed as Imfinzi
Other: Durvalumab-based combination therapies in observational study setting — also filed as Imfinzi
Other: Non Durvalumab-based therapies in observational study setting
Other: Durvalumab-based combination therapies in observational study settings — also filed as Imfinzi

Primary outcome

what the primary-completion date above is the date OF

Real-world overall survival (rwOS) in all participants

measured rwOS will be assessed as OS rates at 6, 12, 18, 24, and 36 months, as applicable per the type of hepatobiliary cancer; median OS for a minimum follow-up of 2 years.

Publications

PMID 41277677 — cited as background

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed